Bacterial toxin may fuel alcohol cravings in heavy drinkers
NCT ID NCT04527185
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a bacterial toxin called endotoxin can increase alcohol consumption in people with alcohol use disorder. 27 participants received either endotoxin or a placebo, and their alcohol intake was measured during a 2-hour session. The goal was to gather early data on how inflammation might affect drinking behavior.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Endotoxin (lipopolysaccharide)
- What this could lead to
- If this study shows a link, it could point toward new ways to understand and treat alcohol use disorder by targeting inflammation.
- What could go wrong
- This is a small, early-phase pilot study with only 27 people. The results may not apply to everyone with alcohol use disorder, and the findings are preliminary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
27 people
The number who actually took part.
- Started
-
Feb 2022
- Finished
-
Oct 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 21-65; 2. Able to read and write English; 3. Meets DSM-5 criteria for current (past 6 months) alcohol use disorder; 4. Drinking criteria: Males - Drinks \> 14 drinks per week and exceeds 4 drinks per day at least twice per week; Females -Drinks \> 7 drinks per week and exceeds 3 drinks per day at least twice per week. 5. Must meet drinking criteria during a consecutive 30-day period within the 90 days prior to baseline; 6. Laboratory sessions will be scheduled such that subjects will not have major responsibilities on the following day which might limit drinking during the self-administration session (e.g., job interview, exam). 7. Negative urine pregnancy test for women. Exclusion Criteria: 1. Participants with any significant current medical conditions (neurological, cardiovascular \[including hypertension or hypotension: sitting BP \>160/100 or \<90/60mmHg at baseline screening\], endocrine, thyroid, renal, liver), seizures, delirium or hallucinations, or other unstable medical conditions including HIV; 2. Current DSM-5 substance use disorders, other than alcohol or nicotine; 3. A positive test result at intake appointment on urine drug screens conducted for illicit drugs, excluding cannabis; 4. Past 30 day use of psychoactive drugs including anxiolytics and antidepressants; 5. Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives \[oral, implant, injection, patch, or ring\], contraceptive sponge, double barrier \[diaphragm or condom plus spermicide\], or IUD); 6. Suicidal, homicidal or evidence of current (past 6-month) severe mental illness such as schizophrenia, bipolar disorder or major depression, or anxiety disorders; 7. Subjects treatment-seeking or who are currently in treatment for alcohol use; 8. Subjects with medical conditions contraindicating alcohol use (e.g., liver enzymes ≥3× normal); 9. Subjects likely to exhibit clinically significant alcohol withdrawal during the study. We will exclude subjects who a) have a history of perceptual distortions, seizures, delirium, or hallucinations upon withdrawal, or b) have a score of \> 8 on the Clinical Institute Withdrawal Assessment scale at intake appointments; 10. Participation within the past 8 weeks in other studies that involve additive blood sampling and/or interventional measures that would be considered excessive in combination with the current application. 11. Subjects \>38 on the Alcohol Use Disorders Identification Test (AUDIT) 12. Subjects with resting pulse \>100 at challenge 13. Subjects with recent (past 2 weeks) acute illness or vaccination 14. Subjects with \>Grade 2 laboratory abnormalities on screening
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale School of Medicine
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Brain-Training games rewire the mind to fight alcohol addiction?
- Can a Stress-Hormone blocker take the edge off alcohol?
- Can MDMA plus therapy help veterans fight both PTSD and alcohol addiction?
- Brain scans probe opioid receptor imbalance in alcohol use disorder
- Spinal taps open a window on alcohol use disorder
- Can a natural alcohol byproduct calm withdrawal? hospital trial tests IV acetate